Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2-DM1 antibody-drug conjugate GQ1001

An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated, via a site-specific linker, to the cytotoxic maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration of anti-HER2-DM1 ADC GQ1001, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, DM1 binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits cell division and the proliferation of tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
Synonym:ADC GQ1001
anti-HER2-DM1 ADC GQ1001
Code name:GQ 1001
GQ-1001
GQ1001
Search NCI's Drug Dictionary